890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCLEleni Tholouli, K. Ardesha, Carlos Bachier et al.|Annals of Oncology|2020Cited by 4